1,647 Shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Bought by Citizens Financial Group Inc. RI

Citizens Financial Group Inc. RI purchased a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 1,647 shares of the medical equipment provider’s stock, valued at approximately $200,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Commonwealth Equity Services LLC increased its holdings in shares of Zimmer Biomet by 0.5% during the third quarter. Commonwealth Equity Services LLC now owns 67,751 shares of the medical equipment provider’s stock worth $7,603,000 after buying an additional 324 shares in the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its position in shares of Zimmer Biomet by 5.7% in the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 40,516 shares of the medical equipment provider’s stock valued at $4,547,000 after purchasing an additional 2,200 shares during the period. Aquila Investment Management LLC boosted its holdings in shares of Zimmer Biomet by 37.5% during the third quarter. Aquila Investment Management LLC now owns 11,000 shares of the medical equipment provider’s stock worth $1,234,000 after acquiring an additional 3,000 shares during the period. Toews Corp ADV acquired a new stake in shares of Zimmer Biomet during the third quarter worth $774,000. Finally, Live Oak Private Wealth LLC grew its holdings in shares of Zimmer Biomet by 1.4% during the 3rd quarter. Live Oak Private Wealth LLC now owns 57,189 shares of the medical equipment provider’s stock worth $6,418,000 after purchasing an additional 776 shares in the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Zimmer Biomet

In related news, VP Chad F. Phipps sold 26,156 shares of the company’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the completion of the sale, the vice president now directly owns 44,145 shares in the company, valued at $5,677,929.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.70% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms have commented on ZBH. TheStreet upgraded shares of Zimmer Biomet from a “c” rating to a “b-” rating in a research note on Thursday, February 8th. Citigroup raised their price target on shares of Zimmer Biomet from $134.00 to $140.00 and gave the stock a “neutral” rating in a report on Wednesday, April 3rd. Truist Financial raised their price objective on shares of Zimmer Biomet from $133.00 to $135.00 and gave the stock a “hold” rating in a report on Friday, February 9th. Canaccord Genuity Group restated a “hold” rating and set a $130.00 target price on shares of Zimmer Biomet in a report on Friday, February 23rd. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 9th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and an average price target of $139.39.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $121.70 on Tuesday. Zimmer Biomet Holdings, Inc. has a 52 week low of $102.00 and a 52 week high of $149.25. The firm has a market capitalization of $25.00 billion, a PE ratio of 24.89, a P/E/G ratio of 2.19 and a beta of 1.01. The company has a quick ratio of 0.78, a current ratio of 1.61 and a debt-to-equity ratio of 0.39. The firm’s 50-day simple moving average is $125.92 and its 200 day simple moving average is $119.80.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share for the quarter, beating the consensus estimate of $2.15 by $0.05. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. The business had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.93 billion. During the same quarter in the previous year, the business posted $1.88 EPS. The business’s quarterly revenue was up 6.3% on a year-over-year basis. On average, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.07 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.79%. The ex-dividend date is Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 19.63%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.